Skip to main content

Table 1 Baseline descriptive statistics

From: Effects of a footwear intervention on foot pain and disability in people with gout: a randomised controlled trial

Variable Footwear intervention group (n = 47) Control group (n = 47)
Sex, male, n (%) 40 (85%) 43 (91%)
Age, years 62.6 (17.0) 62.4 (13.7)
BMI, kg/m2 30.2 (6.4) 32.0 (7.0)
Ethnicity, n (%)
 NZ European 28 (62%) 26 (57%)
 Pacific 6 (13%) 11 (23%)
 Asian 7 (16%) 5 (11%)
 Māori 4 (9%) 4 (9%)
Gout history, mean (SD)
 Disease duration (years) 12.2 (11.2) 13.6 (12.3)
 Flares prior 3 months 0.7 (0.9) 0.4 (0.7)
 Foot tophus, n (%) 9 (19%) 17 (36%)
 Any tophus, n (%) 13 (28%) 24 (51%)
Serum urate, mmol/L 0.39 (0.13) 0.38 (0.11)
Medications, n (%)
 Urate-lowering therapy 33 (72%) 30 (64%)
 Colchicine 15 (33%) 17 (36%)
 Prednisone 9 (20%) 10 (21%)
 NSAID 12 (27%) 13 (29%)
 Diuretic 8 (18%) 5 (11%)
Medical History, n (%)
 Hypertension 22 (48%) 22 (54%)
 Cardiovascular disease 13 (28%) 11 (24%)
 Type 2 diabetes 7 (15%) 3 (7%)
 Peripheral vascular disease 4 (9%) 3 (7%)
 Peripheral neuropathy 3 (7%) 5 (11%)
  1. BMI body mass index, NSAID non-steroidal anti-inflammatory drug